Copyright © 2001 by the European Society of Cardiology.
Hotline Editorial
Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trial
Center for Cardiovascular Disease Prevention and the Leducq Centre for Cardiovascular Research, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, U.S.A.
References
- Shepard J, Cobb SM, Ford I. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–1307
[Abstract/Free Full Text] - Downs JR, Clearfield M, Weis S. Primary prevention of acute coronary events with lovastatin men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA. 1998;279:1615–1622
[Abstract/Free Full Text] - Ridker PM. Evaluating novel cardiovascular risk factors: Can we better predict heart attacks? Ann Intern Med. 1999;130:933–937
[Abstract/Free Full Text] - Garber AM. Using cost-effectiveness analysis to target cholesterol reduction. Ann Intern Med. 2000;132:833–835
[Free Full Text] - Ridker PM, Cushman M, Stampfer MJ, Tracy R, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979
[Abstract/Free Full Text] - Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–843
[Abstract/Free Full Text] - Koenig W, Sund M, Froelich M. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring trends and determinants in cardiovascular disease) Augsberg Cohort Study, 1984 to 1992. Circulation. 1999;99:237–242
[Abstract/Free Full Text] - Danesh J, Whincup P, Wlaker M. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321:199–204
[Abstract/Free Full Text] - Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis. A comparison of C-reactive protein, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001;285:2481–2485
[Abstract/Free Full Text] - Ridker PM, Rifai N, Pfeffer M, Sacks F, Braunwald E. Long-term effects of Pravastatin on plasma concentration of C-reactive protein. Circulation. 1999;100:230–235
[Abstract/Free Full Text] - Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels. The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study. JAMA. 2001;286:64–70
[Abstract/Free Full Text] - Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959–1965
[Abstract/Free Full Text] - Gotto AM Jr, Whitney E, Stein EA. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;101:477–484
[Abstract/Free Full Text] - Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 2001;103:1191–1193
[Abstract/Free Full Text] - Ridker PM, Rifai N, Pfeffer MA. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998;98:839–844
[Abstract/Free Full Text] - Horne BD, Muhlestein JB, Carlquist JF. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol. 2000;36:1774–1780
[Abstract/Free Full Text]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. B. Clearfield C-Reactive Protein: A New Risk Assessment Tool for Cardiovascular Disease J Am Osteopath Assoc, September 1, 2005; 105(9): 409 - 416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M Backes, P. A Howard, and P. M Moriarty Role of C-Reactive Protein in Cardiovascular Disease Ann. Pharmacother., January 1, 2004; 38(1): 110 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M Ridker and on behalf of the JUPITER Study Group Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein: Rationale and Design of the JUPITER Trial* Circulation, November 11, 2003; 108(19): 2292 - 2297. [Full Text] [PDF]
|
|
|
|
 |
|
 G.M. Hirschfield and M.B. Pepys C-reactive protein and cardiovascular disease: new insights from an old molecule QJM, November 1, 2003; 96(11): 793 - 807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Albert, R. J. Glynn, and P. M Ridker Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Circulation, July 15, 2003; 108(2): 161 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E Strandberg, K. Pitkala, S. Berglind, M. S Nieminen, and R. S Tilvis Possibilities of multifactorial cardiovascular disease prevention in patients aged 75 and older: a randomized controlled trial: Drugs and Evidence Based Medicine in the Elderly (DEBATE) Study Eur. Heart J., July 1, 2003; 24(13): 1216 - 1222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-H. Wang, S.-H. Li, R. D. Weisel, P. W.M. Fedak, A. S. Dumont, P. Szmitko, R.-K. Li, D. A.G. Mickle, and S. Verma C-Reactive Protein Upregulates Angiotensin Type 1 Receptors in Vascular Smooth Muscle Circulation, April 8, 2003; 107(13): 1783 - 1790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M Ridker Clinical Application of C-Reactive Protein for Cardiovascular Disease Detection and Prevention Circulation, January 28, 2003; 107(3): 363 - 369. [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Ridker, N. Rifai, L. Rose, J. E. Buring, and N. R. Cook Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events N. Engl. J. Med., November 14, 2002; 347(20): 1557 - 1565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Ridker Inflammatory Biomarkers, Statins, and the Risk of Stroke: Cracking a Clinical Conundrum Circulation, June 4, 2002; 105(22): 2583 - 2585. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||